Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024

Core Insights - Deucrictibant shows a 93% reduction in HAE attack rates and maintains efficacy over long-term use, positioning it as a potential preferred therapy for HAE management [1][2][4] - The median onset of symptom relief for on-demand treatment is approximately 1.1 hours, with a high percentage of attacks resolving within 24 hours [1][5] - The safety and tolerability profile of deucrictibant has been confirmed through multiple studies, indicating no new safety signals [6][4] Prophylactic Program - The CHAPTER-1 study demonstrated that 90% of participants receiving deucrictibant reported well-controlled HAE at week 12 compared to 37.5% in the placebo group [3] - Participants treated with deucrictibant reported higher satisfaction regarding effectiveness and global satisfaction compared to those on placebo [3] On-Demand Program - In the RAPIDe-2 study, the median time to onset of symptom relief was 1.1 hours, with 98.5% of attacks achieving relief within 12 hours [5] - The median time to complete attack resolution was 11.5 hours, with 85.8% of attacks resolving completely within 24 hours [5] - A propensity-score matched analysis indicated that outcomes for attacks treated with deucrictibant were more favorable than those treated with standard care [5] Safety - Cardiovascular safety assessments of deucrictibant showed no adverse effects on cardiovascular parameters in both nonclinical and clinical studies [6] About Deucrictibant - Deucrictibant is a novel oral bradykinin B2 receptor antagonist designed to prevent and treat HAE attacks, with both extended-release and immediate-release formulations under development [8] About Pharvaris - Pharvaris is a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists for HAE, with ongoing Phase 3 studies planned for both prophylactic and on-demand treatment [9]